With just two months remaining in the year, the FDA has approved 37 novel drugs so far - falling short of last year's 46 approvals during the same timeframe. Let's now turn our attention to the biotech stocks awaiting FDA decisions in November.
Journey Medical Corp. (DERM)
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com